Ajjai S Alva
Maisel Research Professor of Translational/Clinical Oncology and Clinical Professor of Internal Medicine
[email protected]

Available to mentor
Ajjai S Alva
Clinical Professor
  • About
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
    • About

    Maisel Research Professor of Clinical and Translational Oncology
    Clinical Professor, Division of Hematology Oncology, Department of Internal Medicine
    Steering Committee Member, ORP NCCN
    University of Michigan Rogel Comprehensive Cancer Center
    Physician Co-Lead, GU Oncology Disease Group
    Hematology-Oncology Peer Review Committee GU Member
    Hematology-Oncology Coordination Committee Member

    Qualifications
    • MS Cell Biology Molecular Genetics
      University of Maryland, College Park, College Park, 2004
    • MB BS
      Jawaharlal Institute of Postgraduate Medical Education and Research, Dhanvantari Nagar, 2000
    • FASCO
      American Society of Clinical Oncology, Alexandria
    Center Memberships
    • Center Member
      Rogel Cancer Center
    Research Overview

    GU oncology Therapeutics
    Biomarkers including ctDNA, Genomics
    Radiomics in Immunotherapy
    Clinical Trials
    Mentoring Trainees in Clinical Research

    Recent Publications See All Publications
    • Journal Article
      Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor.
      Bakaloudi DR, Talukder R, Makrakis D, Diamantopoulos L, Enright T, Leary JB, Patgunarajah U, Thomas VM, Swami U, Agarwal N, Jindal T, Koshkin VS, Brown JR, Barata P, Murgić J, Miletić M, Johnson J, Zakharia Y, Hui G, Drakaki A, Duran I, Buznego LA, Barrera RM, Castañeda DM, Rey-Cárdenas M, Castellano D, Nguyen CB, Park JJ, Alva A, McKay RR, Stewart TF, Epstein IB, Bellmunt J, Wright JL, Gupta S, Grivas P, Khaki AR. Clin Genitourin Cancer, 2024 Aug 12; 22 (6): 102198 DOI:10.1016/j.clgc.2024.102198
      PMID: 39241315
    • Journal Article
      Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043.
      Zakharia Y, Singer EA, Acharyya S, Garje R, Joshi M, Peace D, Baladandayuthapani V, Majumdar A, Li X, Lalancette C, Kryczek I, Zou W, Alva A. Nat Commun, 2024 Feb 1; 15 (1): 972 DOI:10.1038/s41467-024-45216-z
      PMID: 38302476
    • Journal Article
      Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
      Fléchon A, Morales-Barrera R, Powles T, Alva A, Özgüroğlu M, Csöszi T, Loriot Y, Rodriguez-Vida A, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Gunduz S, Mamtani R, Yu EY, Montesa Pino A, Anido U, Sendur MAN, Gravis G, Révész J, Kostorov V, Huillard O, Ma J, Rajasagi M, Vajdi A, Lunceford J, Cristescu R, Imai K, Homet Moreno B, Matsubara N. Clin Cancer Res, 2024 Oct 30; OF1 - OF12. DOI:10.1158/1078-0432.CCR-23-3518
      PMID: 39475359
    • Journal Article
      Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer
      Lerner SP, Tangen C, Svatek RS, Daneshmand S, Pohar KS, Skinner E, Schuckman A, Sagalowsky AI, Smith ND, Kamat AM, Kassouf W, Plets M, Bangs R, Koppie TM, Alva A, La Rosa FG, Pal SK, Kibel AS, Canter DJ, Thompson IM. New England Journal of Medicine, 2024 Oct 3; 391 (13): 1206 - 1216. DOI:10.1056/NEJMoa2401497
    • Journal Article
      1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
      Thapa B, Henderson N, Tagawa ST, Hwang C, Sokolova AO, Bilen MA, Barata PMC, Nguyen CB, Tripathi A, Ayanambakkam A, Graham LS, Zakharia Y, Koshkin VS, Heath E, Dorff TB, Armstrong AJ, McKay RR, Alva AS, Schweizer M, Kilari D. Annals of Oncology, 2024 Sep; 35: s991 DOI:10.1016/j.annonc.2024.08.1724
    • Journal Article
      Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial.
      Lara PN, Tangen C, Heath EI, Gulati S, Stein MN, Meng M, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo R, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Lerner S, Thompson IM, Ryan CW. Eur Urol, 2024 Sep; 86 (3): 258 - 264. DOI:10.1016/j.eururo.2024.05.012
      PMID: 38811313
    • Journal Article
      Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
      Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin M-E, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Eur Urol Oncol, 2024 Aug; 7 (4): 877 - 887. DOI:10.1016/j.euo.2023.11.014
      PMID: 38072760
    • Journal Article
      DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.
      Graham LS, Henderson NC, Kellezi O, Hwang C, Barata PC, Bilen MA, Kilari D, Pierro M, Thapa B, Tripathi A, Mo G, Labriola M, Park JJ, Rothstein S, Garje R, Koshkin VS, Patel VG, Dorff T, Armstrong AJ, McKay RR, Alva A, Schweizer MT. JCO Precis Oncol, 2024 Aug; 8: e2400014 DOI:10.1200/PO.24.00014
      PMID: 39178368